Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|December 1, 2010
Clinical Trials of America Opens New Site
Advertisement
Clinical Trials of America Inc.
has announced the opening of a new Seattle site and named Kathy Hendricks as site manager. Hendricks leads operational and business development and oversees patient recruitment and relations.
“The opening of the Seattle site is the next phase of expansion for Clinical Trials of America,” said President Don Dickerson. “We are leveraging the core strengths of the company’s headquarters in Eugene and building a solid platform beyond Lane County.”
Hendricks brings more than a decade of clinical research and medical assistance experience to her new position and offers a wealth of knowledge to the Clinical Trials of America team. Hendricks has conducted more than 35 clinical trials. She has worked as a clinical research coordinator for research clinics in Washington and North Carolina.
“Her background, training and wide-ranging skill set will be great assets to Clinical Trials of America in the Seattle market,” Dickerson said.
Hendricks can be reached at (206) 769-3175. She reports to Dickerson.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5